Diagnostic journey for individuals with fibrous dysplasia / McCune albright syndrome (FD/MAS)

Kaiyang Song,Roshi Shrestha,Heather Delaney,Rohit Vijjhalwar,Alison Turner,Maria Sanchez,Muhammad Kassim Javaid
DOI: https://doi.org/10.1186/s13023-024-03036-w
2024-02-09
Orphanet Journal of Rare Diseases
Abstract:Reducing delayed diagnosis is a significant healthcare priority for individuals with rare diseases. Fibrous Dysplasia/ McCune Albright Syndrome (FD/MAS) is a rare bone disease caused by somatic activation mutations of NASA. FD/MAS has a broad clinical phenotype reflecting variable involvement of bone, endocrine and other tissues, distribution and severity. The variable phenotype is likely to prolong the diagnostic journey for patients further.
genetics & heredity,medicine, research & experimental
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to reduce the diagnostic delay in patients with Fibrous Dysplasia/McCune - Albright Syndrome (FD/MAS). Specifically, the study aims to describe the time span from the first appearance of symptoms to the final diagnosis in individuals with FD/MAS. This time span is crucial for understanding the diagnostic journey that patients with rare diseases experience in the medical system, especially in diseases like FD/MAS which have a wide range of clinical manifestations and whose diagnostic process can be particularly long and complex. The research background indicates that reducing the diagnostic delay in patients with rare diseases is an important healthcare priority. FD/MAS is a rare bone disease caused by somatic activating mutations in the GNAS gene. Its clinical phenotype is extensive, involving the skeleton, endocrine and other tissues, with varying distribution and severity. This diverse phenotype may further prolong the patient's diagnostic process. Therefore, by analyzing the data in the UK RUDY research database, the researchers explored the time to diagnosis in FD/MAS patients and identified factors that affect the diagnosis time, such as age, gender, and the age at the first appearance of symptoms, in order to provide a basis for improving the diagnostic pathway for patients with rare diseases.